Pterygia: Pathogenesis and the Role of Subconjunctival Bevacizumab in Treatment

REFERENCES

• Coroneo M T, DiGirolamo N, Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol 1999; 10: 282–288
   PubMedGoogle Scholar
• Cogan D G, Kuwabara T, Howard J. The nonelastic nature of pingueculas. Arch Ophthalmol 1959; 61: 388
   Google Scholar
• Dushku N, Reid T W. Immunohistochemical evidence that human pterygia originates from an invasion of vimentin-expressing altered limbal epithelial cells. Curr Eye Res 1994; 13: 473–481
   PubMed Web of Science ®Google Scholar
• Parsons P G, Neale R, Wolski P, Green A. The shady side of solar protection. MJA 1998; 168: 327–330
   PubMedGoogle Scholar
• Coroneo M T. Pterygium as an early indicator of ultraviolet insolation: a hypothesis. Br J Ophthalmol 1993; 77: 734–739
   PubMed Web of Science ®Google Scholar
• Cameron M. Pterygia Throughout the World. Charles C. Thomas, Springfield, IL 1965
   Google Scholar
• Wong W E. A hypothesis on the pathogenesis of pterygia. Ann Ophthalmol 1978; 10: 303–308
   PubMedGoogle Scholar
• Kwok L S, Coroneo M T. A model for pterygium formation. Cornea 1994; 13: 219–224
   PubMed Web of Science ®Google Scholar
• Gans L A. Surgical treatment of pterygium. Focal Points: Clinical Modules for Ophthalmologist. American Academy of Ophthalmology, San Francisco 1996; 14, (12)
   Google Scholar
• Panchapakesan J, Hourihan F, Mitchell P. Prevalence of pterygium and pinguecula: The Blue Mountains eye Study. Am J Ophthalmol 1998; 26(suppl)S2–S5
   Google Scholar
• Nemesure B, Wu S Y, Hennis A, Leske M C. Barbados Eye Studies Group Nine-year incidence and risk factors for pterygium in the barbados eye studies. Ophthalmology Dec, 2008; 115(12)2153–8, Epub 2008 Oct 18
   PubMed Web of Science ®Google Scholar
• Lim R, Mitchell P, Cumming R G. Cataract association with pinguecula and pterygium – the Blue Mountains Eye Study. Am J Ophthalmol 1998; 126: 717–719
   PubMed Web of Science ®Google Scholar
• Garrido C, Carvalho R C, Thorn F, Cruz A AV. Pterygia and cataracts in forest dwelling and riverside indigenous people of the upper amazon basin. Invest Ophthalmol Vis Sci 1998; 39: S1044
   PubMedGoogle Scholar
• Solomon A S. Pterygium. Br J Ophthalmol 2006; 90(6)665–6
   PubMedGoogle Scholar
• DiGirolamo N, Coroneo M, Wakefield D. Epidermal growth factor receptor signaling is partially responsible for the increased matrix metalloproteinase-1 expression in ocular epithelial cells after UVB radiation. Am J Pathol 2005; 167: 489–503
   PubMedGoogle Scholar
• Nolan T M, Di Giorlamo N, Sachdev N H, et al. The role of ultraviolet irradiation and heparin-binding epidermal growth factor-like growth factor in the pathogenesis of pterygium. Am J Pathol 2003; 162: 567–574
   PubMed Web of Science ®Google Scholar
• Tsai Y Y, Cheng Y W, Lee H, et al. Oxidative DNA damage in pterygium. Mol Vis 2005; 11: 71–75
   PubMed Web of Science ®Google Scholar
• Marcovich A L, Morad Y, Sandbank J, Huszar M, Rosner M, Pollack A, et al. Angiogenesis in pterygium: Morphometric and immunohistochemical study. Curr Eye Res 2002; 25(1)17–22
   PubMed Web of Science ®Google Scholar
• Lee D H, Cho H J, Kim J T, Choi J S, Joo C K. Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea 2001; 20: 738–742
   PubMed Web of Science ®Google Scholar
• Jin J, Guan M, Sima J, et al. Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea 2003; 22: 473–477
   PubMed Web of Science ®Google Scholar
• Cameron M E. Histology of pterygium: An electron microscopic study. Br J Ophthalmol 1983; 67: 604–608
   PubMed Web of Science ®Google Scholar
• DiGirolamo N, Tedla N, Lloyd A, et al. Expression of matrix metalloproteinases by human plasma cells and B-lymphocytes. Eur J Immunol 1998; 28: 1773–1784
   PubMedGoogle Scholar
• DiGirolamo N, Verma M J, McCluskey P J, et al. Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis. Curr Eye Res 1996; 15: 1060–1068
   PubMedGoogle Scholar
• DiGirolamo N, Wakefield D, Coroneo M T. UVB-mediated induction of cytokines and growth factors in pterygium epithelial cells involves cell surface receptors and intracellular signaling. Invest Ophthalmol Vis Sci Jun, 2006; 47(6)2430–2437
   PubMedGoogle Scholar
• Hosseini H, Nejabat M, Khalili M R. Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses 2007; 69(4)925–927, Epub 2007 Mar 26
   PubMedGoogle Scholar
• Aspiotis M, Tsanou E, Gorezis S, Ioachim E, Skyrlas A, Stefaniotou M, et al. Angiogenesis in pterygium: Study of microvessel density, vascular endothelial growth factor, and thrombospondin-1. Eye 2006; 21(8)1095–1101
   PubMedGoogle Scholar
• DiGirolamo N, Coroneo M T, Wakefield D. Active matrilysin (MMP-7) in human pterygia: Potential role in angiogenesis. Invest Ophthalmol Vis Sci Aug, 2001; 42(9)1963–1968
   PubMedGoogle Scholar
• Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442–447
   PubMed Web of Science ®Google Scholar
• Prior B. M., Yang H. T., Terjung R. L. What makes vessels grow with exercise training?. J App Physiol 2004; 97: 1119–1128
   PubMed Web of Science ®Google Scholar
• Goto F., Goto K., Weindel K., Folkman J. Synergistic effects of vascular endothelial growth-factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Inves 1993; 69: 508–517
   PubMed Web of Science ®Google Scholar
• Kria L, Ohira A, Amemiya T. Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-β and tumor necrosis factor-α in the pterygium. Acta Histochem 1996; 98: 195–201
   PubMed Web of Science ®Google Scholar
• Taraboletti G, Roberts D, Liotta L A, Giavazzi R. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: A potential angiogenesis regulatory factor. J Cell Biol 1990; 111: 765–772
   PubMed Web of Science ®Google Scholar
• Roberts D D. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J 1996; 10: 1183–1191
   PubMed Web of Science ®Google Scholar
• Frucht-Pery J, Raiskup F, Ilsar M, Landau D, Orucov F, Solomon A. Conjuctival autografting combined with low-dose mitomycin C for prevention of primary pterygium recurrence. Am J Ophthalmol 2006; 141(6)1044–1050
   PubMed Web of Science ®Google Scholar
• Al Fayez M F. Limbal versus conjuctival autograft transplantation for advanced and recurrent pterygium. Ophthalmology 2002; 109(9)1752–1755
   PubMed Web of Science ®Google Scholar
• Fernandes M, Sangwan V S, Bansal A K, et al. Outcome of pterygium surgery: Analysis over 14 years. Eye 2005; 19(11)1182–1190
   PubMedGoogle Scholar
• Esquenazi S. Treatment of early recurrence with topical administration of interferon alpha-2b. Can J Ophthalmol 2005; 40(2)185–187
   PubMedGoogle Scholar
• Tananuvat N, Martin T. The results of amniotic membrane transplantation for primary pterygium compared with conjuctival autograft. Cornea 2004; 23(5)458–463
   PubMedGoogle Scholar
• Pieramici D J, Rabena M D. Anti-VEGF therapy: Comparison of current and future agents. Eye Oct, 2008; 22(10)1330–1336
   PubMed Web of Science ®Google Scholar
• Michelson I C. The mode of development of the vascular system of the retina, with some observations on its significance for central retinal diseases. Eye 1948; 136–180
   Google Scholar
• Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182–1186
   PubMed Web of Science ®Google Scholar
• Li X, Eriksson U. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. Int J Biochem Cell Biol Apr, 2001; 33(4)421–426
   PubMedGoogle Scholar
• Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res Jan, 2008; 33(1)23–28
   PubMed Web of Science ®Google Scholar
• Rosenfeld P J, Moshfeghi A A, Puliafito C A. Optical coherence tomography findings after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthal Surg Lasers Imaging 2005; 36: 331–335
   PubMed Web of Science ®Google Scholar
• Spaide R F, Fisher Y L. Intravitreal bevacizumab (Avastin) treatmentof proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26: 275–278
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342
   PubMed Web of Science ®Google Scholar
• Nguyen Q D, Shah S, Tatlipinar S, et al. Bevacizumab suppresses choroidal neovascularization caused by pathological myopia. Br J Ophthalmol 2005; 89: 1368–1370
   PubMed Web of Science ®Google Scholar
• You I C, Kang I S, Lee S H, Yoon K C. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol Nov 18, 2008
   Google Scholar
• Doctor P P, Bhat P V, Foster C S. Subconjunctival bevacizumab for corneal neovascularization. Cornea Oct, 2008; 27(9)992–995
   PubMedGoogle Scholar
• Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea Feb, 2008; 27(2)142–147
   PubMed Web of Science ®Google Scholar
• Awadein A. Subconjunctival bevacizumab for vascularized rejected corneal grafts. Journal Cataract Refract Surg Nov, 2007; 33(11)1991–1993
   PubMedGoogle Scholar
• Manzano R, Peyman G, Khan P, Carvounis P, Kivilcim M, Ren M, Lake J, Chevez-Barrios P. Inhibition of experimental corneal neovascularization by Bevacizumab (Avastin). Br J Ophthalmol 2007; 91: 804–807
   PubMed Web of Science ®Google Scholar
• Hosseini H, Nejabat M, Mehryar M, Yazdchi T, Sedaghat A, Noori F. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Experiment Ophthalmol 2007; 35: 745–748
   PubMed Web of Science ®Google Scholar
• Fung A E, Rosenfeld P J, Reichel E. The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol Nov, 2006; 90(11)1344–1349
   PubMed Web of Science ®Google Scholar
• Fossarello M, Peiretti E, Zucca I, Perra M T, Serra A. Photodynamic therapy of pterygium with verteporfin: A preliminary report. Cornea 2004; 23(4)330–338
   PubMedGoogle Scholar